Addressing the complexity of the TME with organoids

Immuno-Oncology Insights 2022; 4(1), 115–121

DOI: 10.18609/ioi.2023.015

Published: 19 April 2023
Etienne De Braekeleer

Roisin McGuigan, Editor, Immuno-Oncology Insights, speaks to (pictured) Etienne De Braekeleer, Senior Research Scientist in Discovery Biology, R&D, AstraZeneca

The highly complex tumor microenvironment (TME) represents something of a ‘black box’ to the I–O space, and successful translation of therapies for solid tumor applications remains a challenge for the field. In this interview, Etienne De Braekeleer,  discusses current progress and future applications of organoids to help recapitulate the TME — along with the importance of building more comprehensive datasets from patient samples.